Summary:
A multicenter, randomized, active-control, Phase 3B dtudy to rvaluate the
vardiovascular dafety of Febuxostat and Allopurinol in dubjects with Gout and
Cardiovascular Comorbidities.
Qualified Participants Must:
• Have been diagnosis of Gout
•
Be Diabetic
•
If male be 50 years of age or older
•
If female be 55 years of age or older
•
Have a history of Stroke or Cancer in the last five years
Qualified Participants May Receive:
Be compensated for time and travel if qualified to participate.